Stocks Health care RAJAF
OTC · Health careTFA Therapeutics, Inc. (RAJAF)
TFA Therapeutics, Inc. reported revenue of $1.2M in fiscal 2025, down 0.6% from a year earlier. It posted a net loss of $154.8K. At December 31, 2025 it held $3.2K in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on May 15, 2026.
Key facts about TFA Therapeutics, Inc.
- Net worth
- TFA Therapeutics, Inc. reported shareholders' equity (book value: assets minus liabilities) of -$534.6K at December 31, 2025. We hold no current market value for it.
- Revenue and profit
- In fiscal 2025 revenue was $1.2M (-0.6% year on year), with a net loss of $154.8K.
- Cash flow
- In fiscal 2025 operations used $35.8K of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on May 15, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What TFA Therapeutics, Inc. does
TFA Therapeutics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on OTC under the ticker RAJAF.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.2M | -$154.8K | $0.00 | n/a |
| 2024 | $1.3M | -$226.3K | $0.00 | -$37.2K |
| 2023 | $882.5K | $751.6K | $0.01 | $40.2K |
| 2022 | $53.3K | -$720.1K | -$0.01 | -$321.9K |
| 2022 | $879.3K | -$491K | -$4.91 | -$465.4K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RAJAF ranks in Health care
Latest SEC filings
What TFA Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 2, 2026
- July 27, 2026
- June 25, 2026
- May 15, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue fell 0.6% to $1.2M versus the prior year; diluted EPS $0.00 versus $0.00.
- April 30, 2026Form NT 20-F filing NT 20-F
- November 26, 2025
- September 23, 2025Annual report (foreign issuer, amended) 20-F/A · period to December 31, 2023Revenue rose 1,556% to $882.5K versus the prior year; diluted EPS $0.01 versus -$0.01.
- June 13, 2025Annual report (foreign issuer) 20-F · period to December 31, 2024Revenue rose 42% to $1.3M versus the prior year; diluted EPS $0.00 versus $0.01.
- April 30, 2025Form NT 20-F filing NT 20-F
- December 6, 2024
Insider trades
What the people running TFA Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about RAJAF
What does TFA Therapeutics, Inc. do?
TFA Therapeutics, Inc. is a company in the Health care sector, listed on OTC as RAJAF. Its shares trade on OTC under the ticker RAJAF.
What is TFA Therapeutics, Inc.'s net worth?
TFA Therapeutics, Inc. reported shareholders' equity (book value: assets minus liabilities) of -$534.6K at December 31, 2025. We hold no current market value for it.
Is TFA Therapeutics, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $154.8K on revenue of $1.2M.
How much revenue does TFA Therapeutics, Inc. make?
In fiscal 2025 TFA Therapeutics, Inc. reported revenue of $1.2M. That is 0.6% less than a year earlier.
When did TFA Therapeutics, Inc. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on May 15, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 2, 2026.
Similar companies
Compare RAJAF with
Compare RAJAF with any company
Follow RAJAF
Get an email when TFA Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TFA Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.